Clinical trials: Relapsed Acute Lymphoblastic Leukemia (ALL)
- Condition Relapsed Acute Lymphoblastic Leukemia (ALL)
- Funder type Industry (pharma, biotech, devices)
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia…
- Trial name
- ZUMA-4 (NCT02625480)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 30 sites in United States, Belgium and 9 more
- Volunteers
- 95 people
- Sponsor
- Kite, A Gilead Company
Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
A Study of CTD402 in T-ALL/LBL Patients
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients.
- Trial name
- TENACITY-01 (NCT07070219)
- Testing
- CTD402 CAR T Cell Injection
- Where
- 9 sites in United States, Australia
- Volunteers
- 118 people
- Sponsor
- Imviva Bio
Acute Leukemias, Acute Myeloid Leukemia
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute…
- Conditions
- Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT05521087
- Testing
- JNJ-75276617, Fludarabine, Cytarabine
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute…
- Trial name
- NCT04684147
- Testing
- single dose of CNCT19
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Juventas Cell Therapy Ltd.
B-ALL
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22 CAR-T cell in the treatment of recurrent or refractory B-ALL
- Trial name
- NCT04546906
- Testing
- CD22 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
This phase II trial is studying the safety and potential efficacy of infusing non-human leukocyte antigen matched ex vivo expanded cord blood progenitors with one or two unmanipulated umbilical cord blood units for…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01175785
- Testing
- umbilical cord blood transplantation, fludarabine phosphate, cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nohla Therapeutics, Inc.
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML
This is a Phase I, multi-center, open-label, dose escalation, MTD study of liposomal annamycin in children and young adults with refractory or relapsed ALL or AML.
- Trial name
- NCT00430443
- Testing
- Liposomal Annamycin
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Callisto Pharmaceuticals